 |
| Insulin Sensitizers Market |
The
global insulin sensitizers market is estimated to be valued at US$ 15.09 Bn in 2023 and is expected to
exhibit a CAGR of 5.5% over the
forecast period 2023-2030, as
highlighted in a new report published by Coherent Market Insights.
Market Overview:
Insulin
sensitizers are oral antidiabetic drugs that help manage blood glucose levels
in patients with type 2 diabetes by making cells more sensitive to the effects
of insulin. They are widely used due to their convenience of oral
administration compared to insulin injections.
Market key trends:
One
of the key trends in the insulin sensitizers market is the increasing adoption
of telehealth and remote patient monitoring. The COVID-19 pandemic has
accelerated the shift towards telemedicine as people seek alternatives to
in-person visits. Many insulin sensitizer brands are launching digital health
programs that enable virtual consultations, remote glucose monitoring,
prescription refills, and management of insulin dosages under medical
supervision. This is expected to drive the demand for these drugs over the
forecast period.
Segment Analysis:
The
global insulin sensitizers market is segmented by drug class, drug formulation,
and distribution channel. By drug class, the biguanides segment dominated the
market in 2022 with a market share of over 35%. Biguanides such as metformin
(Glucophage) are front-line therapy for type 2 diabetes due to their
effectiveness, low cost, and safety. By drug formulation, the oral segment held
the largest share of over 80% in 2022 owing to better patient compliance with
oral drugs as compared to injectable drugs. By distribution channel, retail
pharmacies accounted for the highest share in 2022 as retail pharmacies are the
most accessible channel for patients to obtain prescribed drugs.
Key Takeaways:
The Global
Insulin Sensitizers Market Size is expected to reach US$ 22.57 billion by 2030, exhibiting a
CAGR of 5.5% over the forecast
period owing to the rising prevalence of diabetes across the world.
Regional analysis - North America dominated the
market in 2022 and is expected to continue its dominance during the forecast
period. This is attributed to the increasing diabetes patient pool and growing
obesity rates in the region. Asia Pacific is anticipated to witness the fastest
growth during the forecast period.
Key players - Key players operating in the
insulin sensitizers market are Eli Lilly and Company, Novo Nordisk, Sanofi,
Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim,
Johnson & Johnson, and Takeda Pharmaceutical. Eli Lilly and Company leads
the market with its flagship metformin drug Glucophage.
Read More - https://www.trendingwebwire.com/insulin-sensitizers-market-share-and-demand-analysis/
Comments
Post a Comment